Expert Consensus
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 26, 2021; 9(9): 2100-2109
Published online Mar 26, 2021. doi: 10.12998/wjcc.v9.i9.2100
Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain
Hong Xiao, Ke Ma, Dong Huang, Xian-Guo Liu, Tang-Hua Liu, Qing Liu, Guang-Zhao Liu, Tao Song, Wei Tao, Da-Sheng Wu, Yun-Xia Wang, Xiao-Qiu Yang, Xiao-Mei Zhang, Hui Liu, Yan-Qing Liu
Hong Xiao, Hui Liu, Department of Algology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Ke Ma, Department of Algology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
Dong Huang, Department of Algology, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China
Xian-Guo Liu, Department of Physiology and Pain Research Center, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China
Tang-Hua Liu, Department of Algology, The Third People's Hospital of Yibin, Yibin 644000, Sichuan Province, China
Qing Liu, Department of Algology, The Affiliated T.C.M Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
Guang-Zhao Liu, Department of Algology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Tao Song, Department of Algology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Wei Tao, Department of Neurosurgery, Shenzhen University General Hospital, Shenzhen 518055, Guangdong Province, China
Da-Sheng Wu, Department of Algology, The People's Hospital of Jilin Province, Changchun 130021, Jilin Province, China
Yun-Xia Wang, Department of Algology, Hubei Third People’s Hospital of Jianghan University, Wuhan 430033, Hubei Province, China
Xiao-Qiu Yang, Department of Algology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Xiao-Mei Zhang, Department of Algology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China
Yan-Qing Liu, Department of Algology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
Author contributions: Xiao H, Liu H, and Liu YQ conceived the study, designed and performed research, analyzed the data, wrote the paper, and reviewed the manuscript; Ma K, Huang D, Liu XG, Liu TH, Liu Q, Liu GZ, Song T, Tao W, Wu DS, Wang YX, Yang XQ, and Zhang XM performed the research, reviewed the literature, and drafted the manuscript.
Supported by Sichuan Science and Technology Program, No. 2018SZ0386
Conflict-of-interest statement: The authors disclosure no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui Liu, MD, PhD, Professor, Department of Algology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Wuhou District, Chengdu 610041, Sichuan Province, China. 18980601547@qq.com
Received: November 28, 2020
Peer-review started: November 28, 2020
First decision: January 24, 2021
Revised: February 2, 2021
Accepted: March 9, 2021
Article in press: March 9, 2021
Published online: March 26, 2021
Abstract

Neuropathic pain (NPP) is a kind of pain caused by disease or damage impacting the somatosensory system. Ion channel drugs are the main treatment for NPP; however, their irregular usage leads to unsatisfactory pain relief. To regulate the treatment of NPP with ion channel drugs in clinical practice, the Chinese Association for the Study of Pain organized first-line pain management experts from China to write an expert consensus as the reference for the use of ion channels drugs . Here, we reviewed the mechanism and characteristics of sodium and calcium channel drugs, and developed recommendations for the therapeutic principles and clinical practice for carbamazepine, oxcarbazepine, lidocaine, bulleyaconitine A, pregabalin, and gabapentin. We hope this guideline provides guidance to clinicians and patients on the use of ion channel drugs for the management of NPP.

Keywords: Ion channel drug, Neuropathic pain, Expert consensus, Guideline, Gabapentin, Carbamazepine, Oxcarbazepine, Lidocaine, Bulleyaconitine A, Pregabalin

Core Tip: Ion channel drugs are the treatment of choice for neuropathic pain; however, non-adherence to these drugs makes pain relief unsatisfactory. The Chinese Association for the Study of Pain organized first-line pain management experts from across China to write an expert consensus on the guidelines for usage of ion channel drugs. Here, we reviewed the mechanism and characteristics of sodium and calcium channel drugs, and developed recommendations for the therapeutic principles and clinical practice for carbamazepine, oxcarbazepine, lidocaine, bulleyaconitine A (BLA), pregabalin, and gabapentin.